Anti-Estrogen Steroids Faslodex Hormone Fulvestrant 129453-61-8 For Cancer Treatment

Anti-Estrogen Steroids Faslodex Hormone Fulvestrant 129453-61-8 For Cancer Treatment

CAS: 129453-61-8 

Synonyms:Faslodex AstraZeneca

Chemical Name: (7A, 17b)-7-[9-[(4, 4, 5, 5, 5-Pentafluoropentyl)sulfinyl]nonyl]estra-1, 3, 5(10)-triene-3, 17-diol 

Molecular Fomular: C32H47F5O3S 

Molecular Weight: 606.77 

Density: 1.201 g/cm3 

Melting Point: 104-106 

Boiling Point: 674.8 at 760 mmHg 

Appearance: White powder 

Usage: Antineoplastic (hormonal) 

skype:tracyxu123     email tracy at ycphar dot com

Storage: Shading, confined preservation

Usage:Fulvestrant is a type of hormone treatment. It is also called Faslodex. It is a treatment for post menopausal women with advanced breast cancer.A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Also used as an antineoplastic raw materials.

Description:

Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. It is administered as a once-monthly injection.

Application:

Fulvestrant (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.

Fulvestrant is a selective estrogen receptor down-regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant remains under investigation in an attempt to optimize its effectiveness.

Fulvestrant provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy.

In particular 4 clinical trials in this setting did show similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.

Many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Fulvestrant stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.